HK1136773A1 - Treatment of multiple sclerosis (ms) with campath-1h - Google Patents

Treatment of multiple sclerosis (ms) with campath-1h

Info

Publication number
HK1136773A1
HK1136773A1 HK10102029.9A HK10102029A HK1136773A1 HK 1136773 A1 HK1136773 A1 HK 1136773A1 HK 10102029 A HK10102029 A HK 10102029A HK 1136773 A1 HK1136773 A1 HK 1136773A1
Authority
HK
Hong Kong
Prior art keywords
campath
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
HK10102029.9A
Other languages
English (en)
Inventor
Andreas Sachse
David Harris Margolin
Original Assignee
Alcafleu Man Gmbh & Co Kg
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38734000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1136773(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcafleu Man Gmbh & Co Kg, Genzyme Corp filed Critical Alcafleu Man Gmbh & Co Kg
Publication of HK1136773A1 publication Critical patent/HK1136773A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK10102029.9A 2006-09-13 2010-02-26 Treatment of multiple sclerosis (ms) with campath-1h HK1136773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84425106P 2006-09-13 2006-09-13
EP06090169 2006-09-14
PCT/EP2007/008084 WO2008031626A1 (en) 2006-09-13 2007-09-11 Treatment of multiple sclerosis (ms) with campath-1h

Publications (1)

Publication Number Publication Date
HK1136773A1 true HK1136773A1 (en) 2010-07-09

Family

ID=38734000

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10102029.9A HK1136773A1 (en) 2006-09-13 2010-02-26 Treatment of multiple sclerosis (ms) with campath-1h

Country Status (22)

Country Link
EP (4) EP2433649A3 (pt)
JP (6) JP5872756B2 (pt)
KR (2) KR101583587B1 (pt)
CN (1) CN102652832A (pt)
AR (1) AR062779A1 (pt)
BR (1) BRPI0716929A8 (pt)
CA (1) CA2662531A1 (pt)
CY (1) CY2016019I2 (pt)
DK (1) DK2066352T3 (pt)
ES (2) ES2917882T3 (pt)
HK (1) HK1136773A1 (pt)
HR (1) HRP20160211T1 (pt)
HU (2) HUE026740T2 (pt)
IL (3) IL197236A (pt)
LT (1) LTC2066352I2 (pt)
LU (1) LU93092I2 (pt)
MX (2) MX2009002660A (pt)
PL (2) PL2066352T3 (pt)
PT (2) PT3028718T (pt)
RS (1) RS54658B1 (pt)
SI (1) SI2066352T1 (pt)
WO (1) WO2008031626A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2066352T3 (pl) 2006-09-13 2016-05-31 Alcafleu Man Gmbh & Co Kg Leczenie stwardnienia rozsianego (MS) z zastosowaniem Campath-1H
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
RU2016142225A (ru) 2009-05-13 2018-12-18 Джензим Корпорейшн Иммуноглобулины к cd52 человека
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
JP7219721B2 (ja) * 2017-04-21 2023-02-08 ジェンザイム・コーポレーション 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
WO2020123789A1 (en) * 2018-12-12 2020-06-18 Pretzer Aboff Ingrid Vibrational device and methods for mitigating symptoms of freezing of gait

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
PL2066352T3 (pl) 2006-09-13 2016-05-31 Alcafleu Man Gmbh & Co Kg Leczenie stwardnienia rozsianego (MS) z zastosowaniem Campath-1H

Also Published As

Publication number Publication date
JP2010503631A (ja) 2010-02-04
PT2066352E (pt) 2016-03-31
ES2563068T3 (es) 2016-03-10
IL240394B (en) 2018-02-28
SI2066352T1 (sl) 2016-05-31
CY2016019I1 (el) 2016-10-05
MX354080B (es) 2018-02-12
LU93092I2 (de) 2016-08-01
EP2444104A2 (en) 2012-04-25
EP3028718A1 (en) 2016-06-08
IL257341A (en) 2018-03-29
PT3028718T (pt) 2022-06-09
BRPI0716929A8 (pt) 2019-02-05
IL240394A0 (en) 2015-09-24
EP2444104A3 (en) 2012-10-24
KR20150039879A (ko) 2015-04-13
IL197236A (en) 2015-08-31
DK2066352T3 (en) 2016-02-29
EP2433649A2 (en) 2012-03-28
EP2066352B1 (en) 2015-12-02
BRPI0716929A2 (pt) 2013-09-17
PL3028718T3 (pl) 2022-11-21
KR20090063215A (ko) 2009-06-17
HUE026740T2 (en) 2016-07-28
AR062779A1 (es) 2008-12-03
LTPA2016019I1 (lt) 2016-06-27
KR101583587B1 (ko) 2016-01-08
HUS1600028I1 (hu) 2016-07-28
LTC2066352I2 (lt) 2017-09-25
RS54658B1 (en) 2016-08-31
EP3028718B1 (en) 2022-03-23
MX2009002660A (es) 2009-06-11
EP2433649A3 (en) 2012-10-31
RU2009113665A (ru) 2010-10-20
IL197236A0 (en) 2011-08-01
HRP20160211T1 (hr) 2016-03-25
JP6257287B2 (ja) 2018-01-10
ES2917882T3 (es) 2022-07-12
CA2662531A1 (en) 2008-03-20
WO2008031626A1 (en) 2008-03-20
CN102652832A (zh) 2012-09-05
PL2066352T3 (pl) 2016-05-31
JP5872756B2 (ja) 2016-03-01
CY2016019I2 (el) 2016-10-05
JP2014058555A (ja) 2014-04-03
JP2016175929A (ja) 2016-10-06
JP2021107423A (ja) 2021-07-29
AU2007296857A1 (en) 2008-03-20
EP2066352A1 (en) 2009-06-10
JP2018024655A (ja) 2018-02-15
JP2019167385A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
HK1251156A1 (zh) 結節性硬化症治療
IL257341A (en) Treatment of multiple sclerosis with campath–1h
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
AU312971S (en) Patient interface
IL197818A0 (en) Multiple sclerosis therapy
IL192555A0 (en) Method of treating multiple sclerosis
GB0602178D0 (en) Therapeutic treatment
GB0624874D0 (en) Treatment
GB0600692D0 (en) Well treatment
IL193094A0 (en) Improved antitumoral treatments
GB0608655D0 (en) Therapeutic Treatment
AU313136S (en) Patient interface
ZA201000225B (en) Treatment of depression
GB0607952D0 (en) Novel treatment
GB0604460D0 (en) Treatment
GB0618403D0 (en) Treatment of amyotrophic lateral sclerosis
GB0602857D0 (en) The treatment of sialorrhoea
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0609792D0 (en) The treatment of multiple sclerosis
GB0614058D0 (en) Treatment for multiple sclerosis
GB0625602D0 (en) Treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
GB0622040D0 (en) Skin treatment composition
GB0610431D0 (en) Treatment